Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.50 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.50 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | GRIK1 | P39086 | 4/20 | 0.43 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.43 |
| ▸ | GRIA3 | P42263 | 3/20 | 0.43 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.43 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.43 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.43 |
| ▸ | GRIK4 | Q16099 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2238814 | 1.00 | DPP4 (0.50) | DPP4CYP1A2CYP2D6ALOX15CYP2C19 | |
| SCHEMBL7876588 | 1.00 | DPP4 (0.50) | DPP4CYP1A2CYP2D6ALOX15CYP2C19 | |
| SCHEMBL197230 | 1.00 | DPP4 (0.50) | DPP4CYP1A2CYP2D6ALOX15CYP2C19 | |
| SCHEMBL7873502 | 1.00 | DPP4 (0.50) | DPP4CYP1A2CYP2D6ALOX15CYP2C19 | |
| SCHEMBL7876596 | 1.00 | DPP4 (0.50) | DPP4CYP1A2CYP2D6ALOX15CYP2C19 | |
| SCHEMBL29035113 | 1.00 | DPP4 (0.50) | DPP4CYP1A2CYP2D6ALOX15CYP2C19 | |
| Hydrochloric Acid SCHEMBL3418559 | 0.98 | DPP4 (0.49) | DPP4CYP1A2CYP2D6ALOX15CYP2C19 | |
| Hydrochloric Acid SCHEMBL7383848 | 0.98 | DPP4 (0.49) | DPP4CYP1A2CYP2D6ALOX15CYP2C19 | |
| Hydrochloric Acid SCHEMBL18103704 | 0.98 | DPP4 (0.49) | DPP4CYP1A2CYP2D6ALOX15CYP2C19 | |
| Hydrochloric Acid SCHEMBL3418556 | 0.98 | DPP4 (0.49) | DPP4CYP1A2CYP2D6ALOX15CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 178 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118271224-A | Preparation method of (2S, 4S) -4-cyclohexyl-L-proline | 浙江华海药业股份有限公司 | 2024-07-02 | — | — | CN | claimed |
| CN-110885358-A | Vaccine for preventing tumor recurrence and metastasis and application method thereof | 浙江爱睦世医学科技有限公司 | 2020-03-17 | — | — | CN | claimed |
| WO-2019011879-A1 | THERAPEUTIC FOR TREATING CAPILLARY LEAK SYNDROME | HENNING RAINER (CH) | 2019-01-17 | — | — | WO | claimed |
| EP-3154568-A1 | NON-CANONICAL INSULINS AND THEIR USES | California Institute of Technology (US) | 2017-04-19 | — | — | EP | claimed |
| WO-2015191705-A1 | NON-CANONICAL INSULINS AND THEIR USES | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2015-12-17 | — | — | WO | claimed |
| US-20150353619-A1 | Non-Canonical Insulins and Their Uses | CALIFORNIA INSTITUTE OF TECHNOLOGY | 2015-12-10 | — | — | US | claimed |
| US-20120142939-A1 | PROCESS FOR THE PREPARATION OF FOSINOPRIL AND INTERMEDIATES THEREOF | DIPHARMA FRANCIS S.R.L. (IT) | 2012-06-07 | — | — | US | claimed |
| EP-2460808-A1 | Process for the preparation of fosinopril and intermediates thereof | Dipharma Francis S.r.l. (IT) | 2012-06-06 | — | — | EP | claimed |
| US-8088890-B2 | Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2012-01-03 | — | — | US | claimed |
| EP-2334324-A2 | BBETA (15-42) AND ITS ANALOGUES COMBINED WITH CYCLOSPORINE FOR TREATMENT OF REPERFUSION INJURY | Fibrex Medical Research & Development GmbH (AT) | 2011-06-22 | — | — | EP | claimed |
| US-20090286739-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2009-11-19 | — | — | US | claimed |
| WO-2009137850-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2009-11-19 | — | — | WO | claimed |
| CN-101462996-A | Preparation of 4-cyclohexyl proline derivative | SHANGHAI INST PHARM INDUSTRY (CN) | 2009-06-24 | — | — | CN | claimed |
| US-7078532-B2 | Process for manufacture of fosinopril sodium | LUPIN LABORATORIES LIMITED (IN) | 2006-07-18 | — | — | US | claimed |
| US-20040225127-A1 | Process for manufacture of fosinopril sodium | LUPIN LABORATORIES LIMITED (IN) | 2004-11-11 | — | — | US | claimed |
| EP-1383779-A2 | A PROCESS FOR MANUFACTURE OF FOSINOPRIL SODIUM | LUPIN LABORATORIES LIMITED (IN) | 2004-01-28 | — | — | EP | claimed |
| WO-2002088149-A2 | A PROCESS FOR MANUFACTURE OF FOSINOPRIL SODIUM | LUPIN LABORATORIES LIMITED (IN) | 2002-11-07 | — | — | WO | claimed |
| EP-0437799-B1 | The diastereoselective preparation of phosphinate esters | SQUIBB & SONS INC (US) | 1995-02-22 | — | — | EP | claimed |
| EP-0437799-A1 | The diastereoselective preparation of phosphinate esters | E.R. SQUIBB & SONS, INC. (US) | 1991-07-24 | — | — | EP | claimed |
| US-5008399-A | Reacting phosphinic acid ester with halo ester in presence of specific base in organic solvent, hydrogenating | E. R. SQUIBB & SONS, INC. (US) | 1991-04-16 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142939-A1 | PROCESS FOR THE PREPARATION OF FOSINOPRIL AND INTERMEDIATES THEREOF | FOS, FOSB, NPPA | DPP4 281/4885CYP1A2 1885/4885CYP2D6 1634/4885 |
| US-20150353619-A1 | Non-Canonical Insulins and Their Uses | IAPP, IDE, INSR | DPP4 37/4885CYP1A2 2895/4885CYP2D6 2420/4885 |
| US-20040225127-A1 | Process for manufacture of fosinopril sodium | FOS, FOSB, AGT | DPP4 194/4885CYP1A2 457/4885CYP2D6 340/4885 |
| US-20090286739-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | NPR3, RXFP3, RXFP1 | DPP4 2036/4885CYP1A2 2247/4885CYP2D6 2251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.